Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinomaKohei Shigeta(Massachusetts General Hospital), Dan G. Duda(Massachusetts General Hospital)Journal for ImmunoTherapy of CancerNovember 1, 202010.1136/jitc-2020-001435Cited by 149SaveCiteExport RISWatch citationsRelated PapersAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?|Angiogenesis|2017|690CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice|Hepatology|2014|456Dual Programmed Death Receptor‐1 and Vascular Endothelial Growth Factor Receptor‐2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma|Hepatology|2019|404